UroGen Reports Results Of First Post-Commercial Utilization Review Of JELMYTO

UroGen Pharma Ltd. (URGN) reported results from the first post-commercial utilization review of JELMYTO for pyelocalyceal solution. JELMYTO is approved for the treatment of adults with LG-UTUC, or low-grade upper tract urothelial cancer.

"This study provides valuable insights into how physicians are utilizing JELMYTO in the real-world and reinforces the genuine clinical value of this therapy for patients with LG-UTUC," said Mark Schoenberg, Chief Medical Officer, UroGen.

The study evaluated 132 patients treated with JELMYTO from 15 high-volume academic and community centers and characterized the manner in which urologists are now using JELMYTO in their practices. It was found that doctors are using JELMYTO for the treatment of large tumors, high grade tumors, and ureteral tumors. Primary chemoablation resulted in a 70% complete response rate for patients with tumors less
than 1cm while 69% achieved complete response when JELMYTO was combined with laser ablation.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Follow RTT